StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research note released on Thursday. The firm issued a sell rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.00 on Thursday. The firm has a market cap of $100,084.00, a PE ratio of -0.02 and a beta of 1.47. Navidea Biopharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.15.
Navidea Biopharmaceuticals Company Profile
See Also
- Five stocks we like better than Navidea Biopharmaceuticals
- Consumer Discretionary Stocks Explained
- 3 Leveraged ETFs to Multiply Returns
- Roth IRA Calculator: Calculate Your Potential Returns
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- High Flyers: 3 Natural Gas Stocks for March 2022
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.